EN
InnoCare Pharma Limited Just Beat Revenue Estimates By 39%
Last week, you might have seen that InnoCare Pharma Limited (HKG:9969) released its third-quarter result to the market. The early response was not positive, with shares down 4.4% to HK$11.25 in the past week. Revenue of CN¥962m came in a notable 39% ahead of expectations, while statutory earnings of CN¥0.14 were in line with what the analysts had been forecasting. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Following the recent earnings report, the consensus from eight analysts covering InnoCare Pharma is for revenues of CN¥2.96b in 2027. This implies a chunky 12% decline in revenue compared to the last 12 months. Statutory earnings per share are forecast to dive 72% to CN¥0.22 in the same period. In the lead-up to this report, the analysts had been modelling revenues of CN¥2.93b and earnings per share (EPS) of CN¥0.16 in 2027. Although the revenue estimates have not really changed, we can see there's been a very substantial lift in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.
Check out our latest analysis for InnoCare Pharma
The consensus price target was unchanged at HK$18.80, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic InnoCare Pharma analyst has a price target of HK$23.18 per share, while the most pessimistic values it at HK$8.94. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 9.6% by the end of 2027. This indicates a significant reduction from annual growth of 29% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 23% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - InnoCare Pharma is expected to lag the wider industry.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards InnoCare Pharma following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that InnoCare Pharma's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for InnoCare Pharma going out to 2028, and you can see them free on our platform here..
And what about risks? Every company has them, and we've spotted 3 warning signs for InnoCare Pharma (of which 2 can't be ignored!) you should know about.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.